军事知识服务平台
单核细胞增生李斯特菌为载体的肿瘤疫苗研究进展
Research advances in Listeria monocytogenes-based tumor vaccines
摘要 单核细胞增生李斯特菌因其独特的生物学特性和免疫学优势,逐渐成为肿瘤免疫治疗的新选择,在多种临床前癌症模型以及临床试验中展现出可观的治疗收益.该文阐述了单核细胞增生李斯特菌的生物特性、免疫应答方式和减毒策略,并对其在多种肿瘤免疫治疗中的应用进行系统综述,详细介绍了不同免疫治疗疫苗的研究现状和优缺点,同时对当前面临的问题、解决手段以及未来发展方向进行了分析,以期为后续肿瘤治疗新技术、新策略的开发提供有价值见解和开创性思路.
Abstract:
Listeria monocytogenes has emerged as a promising vector platform for tumor immunotherapy,leveraging its unique biological properties and immunological advantages.Significant therapeutic efficacy has been demonstrated across diverse pre-clinical cancer models and clinical trials.This review elaborates on the biological characteristics of Listeria monocytogenes,its immunological response mechanisms,and attenuation strategies.It systematically summarizes its applications in various tumor immunotherapies,detailing the research status,advantages,and limitations of different immunotherapeutic vaccines.Further-more,the analysis addresses current challenges,potential solutions,and future research trajectories aims to provide valuable in-sights and pioneering perspectives for developing next-generation tumor therapeutic technologies and strategies.
刊 名 生物技术
年,卷(期): 2026, 36(3)
分类号: Q939.9
机标分类号: R730.51 R392.11 R979.1
在线出版日期: 2026年8月6日
基金项目: :重庆市公共卫生重点专(学)科建设项目,